Search
Stannous chloride
go.drugbank.com/drugs/DB11056ApprovedTin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700]. … These complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue [FDA Label].
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis. … Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease.
Zinc finger and BTB domain-containing protein 7A
go.drugbank.com/bio_entities/BE0012406TargetHumansAlso directly interacts with transcription factors like SP1 to prevent their binding to DNA (PubMed:12004059). … Collaborates with transcription factors like RELA to modify the accessibility of gene transcription regulatory regions to secondary transcription factors (By similarity).
Synonyms: Factor that binds to inducer of short transcripts protein 1Flavin adenine dinucleotide
go.drugbank.com/drugs/DB03147Approved(Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [L34393] In January 2024, Biogen announced that the development and commercialization of aducanumab will be discontinued to prioritize the marketing of [lecanemab], another drug approved for the treatment
Azelaic acid
go.drugbank.com/drugs/DB00548ApprovedInvestigationalAzelaic acid's antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis. … Azelaic acid is effective against a number of skin conditions, such as mild to moderate acne, when applied topically in a cream formulation of 20%.
Categories: Anti-Acne Preparations for Topical UseEtryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnIn the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was … Similarly to MDMA, αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesLanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018. … Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection.
Cyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnCyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries. … A direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia.
Mefloquine
go.drugbank.com/drugs/DB00358Approved, and immigrants traveling to their place of origin. … [L30623] Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum.